Proteomic Biomarkers to Guide Stratification for Covid-19 Treatment: Exemplifying a Path Forward Toward Implementation?

Proteins and peptides serve as biomarkers in the context of multiple pathologies. The hypothesis that protein or peptide biomarkers may also be of value in the context of the Covid-19 pandemic appears self-evident. Proteome based biomarkers are not expected to display significant added value in the detection of viral infection but appear well suited to address a major unmet need: the prognosis of the course of disease, to guide appropriate, timely intervention. Based on similar approaches in the context of other diseases and using a CE-MS platform, urinary peptides are investigated for their value as biomarkers to assess disease progression after SARS-CoV-2 infection. The manuscript presented in this issue of Proteomics reports first results, indicating that urine peptides may be of substantial value in the assessment and prediction of severity of the Covid-19 disease course on an individual level. While the findings are not entirely surprising, the report does stand out from all others by a well-defined context-of-use, and, what is more, by presenting an already initiated validation study that may, if successful, result in immediate implementation of this proteomics-based diagnostic test. This approach should serve as positive example for the planning and execution of clinical proteomics studies